Developer docs
API playgroundTry for free, no card

Search company profiles

Clinilabs

Full company profile

uuid0006eyk

Namestring
Clinilabs
Legal namestring
Clinilabs
Websiteurl
clinilabs.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Clinilabs is a privately-held, full-service contract research organization (CRO) founded in 2000 by Dr. Gary Zammit and headquartered in Eatontown, New Jersey. The company is purpose-built for central nervous system (CNS) drug, device, and technology development, serving as the only full-service CRO exclusively focused on neurotherapeutics across psychiatry, neurology, substance use disorders, and rare CNS conditions. Clinilabs reports 25+ years of CNS-specific experience, 800+ completed clinical trials, and contributions to 30+ marketed products across 25+ indications, with 17 of the top 20 global pharmaceutical companies among its clients.

The company's product portfolio spans the full clinical development lifecycle. Core services include Early Phase Development (Phase 1 SAD/MAD, PK/PD, drug-drug interaction studies) executed at two owned Phase 1 clinical research units (100 beds total across Eatontown, NJ and Midtown Manhattan), Phase 2–4 Trial Management for global multicenter studies, and centralized Corelab data services (PSG, EEG, qEEG, ECG, actigraphy, EMG, video ratings) operating from seven laboratories worldwide. Underlying technology is anchored by Clinical InSite™, a proprietary electronic data and document management platform with validated audit trails, remote monitoring, and permission-based file sharing; Clinical InSite 2.0 extends the platform to ingest wearable and medical device data streams via API. Supporting offerings include the Accelerator Sites™ program for accelerated study startup, Placebo Response Management services, Advisory & Regulatory Support (FDA/EMA), and MedTech Clinical Services for 510(k)/PMA pathways.

Clinilabs generates revenue through professional-services, project-based CRO fees structured around trial scope, phase, complexity, and duration. The go-to-market is enterprise-direct, targeting pharmaceutical, biotechnology, and medical device companies through RFP submissions, a dedicated business development team, scientific advisory board credibility, and 15+ annual CNS industry conferences (AAIC, ECNP, FENS, CTAD, CNS Summit, BIO-Europe). Global delivery is supported by owned infrastructure in the US, regional offices in Paris, Basel (EU HQ established Feb 2026), Beijing, and Tokyo, and an investigator network spanning 42 countries. The company is GDPR-compliant, completed a 2026 FDA inspection with no findings, and received a 2025 growth investment from InTandem Capital Partners.

Short descriptiontext

Clinilabs is a privately-held, full-service CRO founded in 2000 that exclusively manages central nervous system (CNS) drug, device, and technology clinical trials from Phase 1 through Phase 4. It serves top global pharmaceutical companies, biotechnology firms, and MedTech developers across psychiatry, neurology, substance use, and rare CNS disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersEatontown, United States
HQ citystring
Eatontown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, CNS therapeutics trials, early phase development, central nervous system trials
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

Clinilabs generates revenue through full-service contract research organization (CRO) fees for managing CNS drug, device, and technology clinical trials. Services span Phase 1-4 trial management, including early phase development, clinical research unit operations, corelab services, and regulatory advisory. Revenue is project-based with fees structured around scope, duration, and complexity of trials.

clinilabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Clinilabs is a full-service Contract Research Organization (CRO) exclusively focused on clinical development services for central nervous system (CNS) drugs, devices, and technologies. The company manages Phase 1 through Phase 4 trials, operating two Phase 1 clinical research units (100 beds total), a centralized Corelab for PSG/EEG data processing, and a proprietary Clinical InSite data management platform. Service offerings include early phase development, Phase 2-4 trial management, centralized corelab data services, advisory and regulatory support, MedTech clinical trials, the Accelerator Sites program, and placebo response management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Top-line results delivered just 7 days after database lock for Alzheimer's disease trial
+4 more records
Product overview1 text field

Clinilabs is a full-service CNS CRO offering integrated, end-to-end neurotherapeutic clinical trial services across the drug development lifecycle. The portfolio comprises Early Phase Development (Phase 1) and Phase 2-4 Trial Management as the core clinical services, supported by two Physical Clinical Research Units (100 beds across NJ and NYC), the centralized Corelab data services, and a proprietary Clinical InSite technology platform. The Accelerator Sites program and Placebo Response Management service are specialty offerings that enhance site selection and trial quality. Advisory & Regulatory Support and MedTech Clinical Services extend the portfolio to device development. All services are unified under a single CNS therapeutic focus, with the Clinical InSite platform serving as the central data management layer connecting eCRF systems (Medidata RAVE, Medrio), Veeva Vault, and wearable/device data streams.

Product and service1 record
1Early Phase Development
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-sized, scientifically focused CRO with strong CNS, neuroscience, and rare disease expertise. Closest direct competitor to Clinilabs in therapeutic-area specialty CRO positioning, with comparable global trial management and central lab offerings.

TypeDirect peer
Description

Specialty CRO with deep CNS, neuroscience, and rare disease therapeutic-area focus, plus pediatrics and oncology. Competes head-to-head with Clinilabs for biotech and mid-pharma CNS trial work.

TypeDirect peer
Description

Mid-tier full-service CRO with strong CNS/neurology, metabolic, and oncology franchises. Competes with Clinilabs for Phase 2-4 trial outsourcing from biotech and pharma sponsors, with comparable sponsor relationships.

TypeBroad incumbent
Description

Largest global CRO with broad therapeutic-area coverage including dedicated CNS and neuroscience teams. Competes for the same RFPs but typically on global scale and integrated technology rather than CNS therapeutic specialization.

TypeBroad incumbent
Description

Large global full-service CRO with neuroscience and CNS therapeutic expertise as part of broader portfolio. Competes with Clinilabs particularly for late-stage CNS trials from top pharmaceutical sponsors.

TypeBroad incumbent
Description

Large biopharmaceutical solutions organization combining CRO and commercial services, with neuroscience capabilities. Competes in CNS trial management alongside broader portfolio offerings.

TypeBroad incumbent
Description

Large CRO/CDMO with preclinical and clinical CNS/neuroscience capabilities. Overlaps with Clinilabs on early-phase CNS studies and provides a comparator for sponsor procurement decisions.

TypeEmerging player
Description

Smaller specialty clinical research services provider focused on CNS and rare disease trials. Comparable in therapeutic focus but smaller in scale, geographic reach, and proprietary technology stack.

TypeRegional player
Description

European-headquartered mid-size CRO with CNS, dermatology, and oncology franchises. Competes with Clinilabs in European CNS trial work and shares overlap in sponsor relationships, especially Nordic and EU biotech.

TypeOthers
Description

Clinical-stage CNS biopharma company developing neurotherapeutics. Not a direct CRO competitor but a representative CNS sponsor in Clinilabs' target customer set, illustrating the kind of biotech clients Clinilabs serves.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clinilabs

Clinical Research Servicesclinilabs.com

Clinilabs is a privately-held, full-service CRO founded in 2000 that exclusively manages central nervous system (CNS) drug, device, and technology clinical trials from Phase 1 through Phase 4. It serves top global pharmaceutical companies, biotechnology firms, and MedTech developers across psychiatry, neurology, substance use, and rare CNS disorders.

What Clinilabs does

Clinilabs is a privately-held, full-service contract research organization (CRO) founded in 2000 by Dr. Gary Zammit and headquartered in Eatontown, New Jersey. The company is purpose-built for central nervous system (CNS) drug, device, and technology development, serving as the only full-service CRO exclusively focused on neurotherapeutics across psychiatry, neurology, substance use disorders, and rare CNS conditions. Clinilabs reports 25+ years of CNS-specific experience, 800+ completed clinical trials, and contributions to 30+ marketed products across 25+ indications, with 17 of the top 20 global pharmaceutical companies among its clients.

The company's product portfolio spans the full clinical development lifecycle. Core services include Early Phase Development (Phase 1 SAD/MAD, PK/PD, drug-drug interaction studies) executed at two owned Phase 1 clinical research units (100 beds total across Eatontown, NJ and Midtown Manhattan), Phase 2–4 Trial Management for global multicenter studies, and centralized Corelab data services (PSG, EEG, qEEG, ECG, actigraphy, EMG, video ratings) operating from seven laboratories worldwide. Underlying technology is anchored by Clinical InSite™, a proprietary electronic data and document management platform with validated audit trails, remote monitoring, and permission-based file sharing; Clinical InSite 2.0 extends the platform to ingest wearable and medical device data streams via API. Supporting offerings include the Accelerator Sites™ program for accelerated study startup, Placebo Response Management services, Advisory & Regulatory Support (FDA/EMA), and MedTech Clinical Services for 510(k)/PMA pathways.

Clinilabs generates revenue through professional-services, project-based CRO fees structured around trial scope, phase, complexity, and duration. The go-to-market is enterprise-direct, targeting pharmaceutical, biotechnology, and medical device companies through RFP submissions, a dedicated business development team, scientific advisory board credibility, and 15+ annual CNS industry conferences (AAIC, ECNP, FENS, CTAD, CNS Summit, BIO-Europe). Global delivery is supported by owned infrastructure in the US, regional offices in Paris, Basel (EU HQ established Feb 2026), Beijing, and Tokyo, and an investigator network spanning 42 countries. The company is GDPR-compliant, completed a 2026 FDA inspection with no findings, and received a 2025 growth investment from InTandem Capital Partners.

Clinilabs firmographics

Firmographics
Name
Clinilabs
Legal name
Clinilabs
Website
https://clinilabs.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
101–250 employees
Short description
Clinilabs is a privately-held, full-service CRO founded in 2000 that exclusively manages central nervous system (CNS) drug, device, and technology clinical trials from Phase 1 through Phase 4. It serves top global pharmaceutical companies, biotechnology firms, and MedTech developers across psychiatry, neurology, substance use, and rare CNS disorders.
Ownership category
akta.pro rank

Clinilabs industry classification

Industry
Product category
Clinical Research Services
NAICS
Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Clinical research services
  • Contract research organization
  • CNS therapeutics trials
  • Early phase development
  • Central nervous system trials

Where Clinilabs is headquartered

Location

Headquarters

HQ city
Eatontown
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Clinilabs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Organization Services: Clinilabs generates revenue through full-service contract research organization (CRO) fees for managing CNS drug, device, and technology clinical trials. Services span Phase 1-4 trial management, including early phase development, clinical research unit operations, corelab services, and regulatory advisory. Revenue is project-based with fees structured around scope, duration, and complexity of trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Clinilabs product offering

Product offering

Core offering

Clinilabs is a full-service Contract Research Organization (CRO) exclusively focused on clinical development services for central nervous system (CNS) drugs, devices, and technologies. The company manages Phase 1 through Phase 4 trials, operating two Phase 1 clinical research units (100 beds total), a centralized Corelab for PSG/EEG data processing, and a proprietary Clinical InSite data management platform. Service offerings include early phase development, Phase 2-4 trial management, centralized corelab data services, advisory and regulatory support, MedTech clinical trials, the Accelerator Sites program, and placebo response management.

Product overview

Clinilabs is a full-service CNS CRO offering integrated, end-to-end neurotherapeutic clinical trial services across the drug development lifecycle. The portfolio comprises Early Phase Development (Phase 1) and Phase 2-4 Trial Management as the core clinical services, supported by two Physical Clinical Research Units (100 beds across NJ and NYC), the centralized Corelab data services, and a proprietary Clinical InSite technology platform. The Accelerator Sites program and Placebo Response Management service are specialty offerings that enhance site selection and trial quality. Advisory & Regulatory Support and MedTech Clinical Services extend the portfolio to device development. All services are unified under a single CNS therapeutic focus, with the Clinical InSite platform serving as the central data management layer connecting eCRF systems (Medidata RAVE, Medrio), Veeva Vault, and wearable/device data streams.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early Phase Development

Quantifiable outcome

  • Top-line results delivered just 7 days after database lock for Alzheimer's disease trial
  • +4 more outcomes

Companies that use Clinilabs

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Clinilabs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Clinilabs partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Clinilabs competitors and assessment

Company assessment

Direct peers

  • Worldwide Clinical Trials: Mid-sized, scientifically focused CRO with strong CNS, neuroscience, and rare disease expertise. Closest direct competitor to Clinilabs in therapeutic-area specialty CRO positioning, with comparable global trial management and central lab offerings.
  • Premier Research: Specialty CRO with deep CNS, neuroscience, and rare disease therapeutic-area focus, plus pediatrics and oncology. Competes head-to-head with Clinilabs for biotech and mid-pharma CNS trial work.
  • Medpace: Mid-tier full-service CRO with strong CNS/neurology, metabolic, and oncology franchises. Competes with Clinilabs for Phase 2-4 trial outsourcing from biotech and pharma sponsors, with comparable sponsor relationships.

Broad incumbents

  • IQVIA: Largest global CRO with broad therapeutic-area coverage including dedicated CNS and neuroscience teams. Competes for the same RFPs but typically on global scale and integrated technology rather than CNS therapeutic specialization.
  • Parexel International: Large global full-service CRO with neuroscience and CNS therapeutic expertise as part of broader portfolio. Competes with Clinilabs particularly for late-stage CNS trials from top pharmaceutical sponsors.
  • Syneos Health: Large biopharmaceutical solutions organization combining CRO and commercial services, with neuroscience capabilities. Competes in CNS trial management alongside broader portfolio offerings.
  • Charles River Laboratories: Large CRO/CDMO with preclinical and clinical CNS/neuroscience capabilities. Overlaps with Clinilabs on early-phase CNS studies and provides a comparator for sponsor procurement decisions.

Emerging players

  • BioPhase Solutions: Smaller specialty clinical research services provider focused on CNS and rare disease trials. Comparable in therapeutic focus but smaller in scale, geographic reach, and proprietary technology stack.

Regional players

  • TFS HealthScience: European-headquartered mid-size CRO with CNS, dermatology, and oncology franchises. Competes with Clinilabs in European CNS trial work and shares overlap in sponsor relationships, especially Nordic and EU biotech.

Others

  • Cyclerion Therapeutics: Clinical-stage CNS biopharma company developing neurotherapeutics. Not a direct CRO competitor but a representative CNS sponsor in Clinilabs' target customer set, illustrating the kind of biotech clients Clinilabs serves.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key highlights7 records

Customer concentration

Clinilabs social profiles

Digital presence

Clinilabs compliance and trust

Trust signal

Compliance1 record

Clinilabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clinilabs leadership team

Management profile

Number of profiles

Profiles10 records

Clinilabs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Clinilabs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clinilabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clinilabs

What does Clinilabs do?

Clinilabs is a full-service Contract Research Organization (CRO) exclusively focused on clinical development services for central nervous system (CNS) drugs, devices, and technologies. The company manages Phase 1 through Phase 4 trials, operating two Phase 1 clinical research units (100 beds total), a centralized Corelab for PSG/EEG data processing, and a proprietary Clinical InSite data management platform. Service offerings include early phase development, Phase 2-4 trial management, centralized corelab data services, advisory and regulatory support, MedTech clinical trials, the Accelerator Sites program, and placebo response management.

Is Clinilabs a public or private company?

Clinilabs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Clinilabs founded?

Clinilabs was founded in 2000. It employs 101 to 250 people.

Where is Clinilabs based?

Clinilabs is headquartered in Eatontown, United States, in the North America region.

How does Clinilabs make money?

One revenue line is on record: contract Research Organization Services.

Who are Clinilabs's main competitors?

Direct peers on record are Worldwide Clinical Trials, Premier Research and Medpace. Broad incumbents are IQVIA, Parexel International, Syneos Health and Charles River Laboratories. BioPhase Solutions is listed as an emerging player. TFS HealthScience is listed as a regional player. Cyclerion Therapeutics is listed as an others.

Does Clinilabs have an API?

No public API is recorded for Clinilabs.

What industry is Clinilabs in?

Clinilabs's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceClinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive ChairpersonClinilabs announced leadership expansion, appointing Laura Shannon as Chief Executive Officer and promoting founder Gary Zammit to Executive Chairperson. Shannon brings over 30 years of biopharma experience, including a role at IQVIA. The move supports Clinilabs' global CNS drug and device development focus.citybizClinilabs Names Laura Shannon CEO; Founder Gary Zammit Becomes Executive ChairpersonClinilabs has appointed Laura Shannon as Chief Executive Officer, transitioning founder Gary Zammit to Executive Chairperson as the organization seeks to expand its global operations. Shannon, who has over 30 years of biopharmaceutical industry experience, will lead Clinilabs' continued international growth, particularly in Europe. Zammit remains involved as Executive Chairperson, emphasizing Shannon's expertise in guiding the company through this next phase of development.FinancialContent Business PageClinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive ChairpersonClinilabs announced the appointment of Laura Shannon as its new Chief Executive Officer, while founder Gary Zammit transitioned to the role of Executive Chairperson. This leadership change supports the company's expansion into Europe and its strategic focus on CNS drug and device development across global markets.Business Wire BlogClinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive ChairpersonClinilabs announced leadership expansion, appointing Laura Shannon as Chief Executive Officer and promoting founder Gary Zammit to Executive Chairperson. Shannon brings over 30 years of biopharma experience, including as EVP and Chief Commercial Officer at IQVIA. The move supports Clinilabs' global CNS drug and device development focus.FinanzNachrichten.deClinilabs gibt Ernennungen in der medizinischen Führungsspitze bekanntClinilabs announced the appointment of Dr. Bob Dagher as Chief Medical Officer and Dr. Waqar Ahmed Siddiqui as Principal Investigator at its clinical research unit in Eatontown, New Jersey. Dr. Dagher brings over 20 years of experience in clinical development, Medical Affairs, and regulatory strategy across neuropsychiatry, neuroimmunology, and rare diseases, having served as CMO at four biotechnology companies. The company stated these appointments will strengthen its ability to support sponsors in advancing innovative CNS therapies from early-stage development through regulatory approval.Business Wire BlogClinilabs Announces Medical Leadership AppointmentsClinilabs, a contract research organization specializing in CNS drug and device development, announced the appointments of Bob Dagher, M.D. as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D. as Principal Investigator at its Eatontown, New Jersey clinical research unit. Dr. Dagher brings over 20 years of executive leadership experience across clinical development, medical affairs, and regulatory strategy, having served as CMO for four biotech companies. The appointments are intended to strengthen Clinilabs' ability to guide sponsors through complex development programs and support the delivery of new therapies for psychiatric, neurological, and rare CNS disorders.FinancialContent Business PageClinilabs Announces Medical Leadership AppointmentsClinilabs announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator. These appointments aim to enhance the company's leadership in CNS drug and device development, supporting clinical programs for psychiatric and neurological disorders.MorningstarClinilabs Announces Medical Leadership AppointmentsClinilabs appointed Bob Dagher as Chief Medical Officer and Waqar Ahmed Siddiqui as Principal Investigator of its Eatontown, New Jersey Clinical Research Unit. Dagher brings over 20 years of executive leadership in clinical development and regulatory strategy, while Siddiqui leads clinical research execution. The appointments aim to support clinical programs for CNS disorders.BioSpaceRoutine FDA Inspection Completed Successfully With No Findings for ClinilabsClinilabs announced a successful routine FDA inspection with no findings. The inspection covered clinical operations, data integrity, and regulatory compliance. The outcome reflects the company's commitment to quality and patient safety.Business Wire BlogRoutine FDA Inspection Completed Successfully With No Findings for ClinilabsClinilabs, a contract research organization specializing in CNS drug and device development, has successfully completed a routine inspection by the U.S. Food and Drug Administration with no observations or findings. The FDA reviewed multiple aspects of Clinilabs' clinical operations, including data integrity and adherence to regulatory requirements. The company's CEO attributed the outcome to the organization's quality culture, disciplined teams, and focus on patient safety and regulatory readiness.